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Background: MicroRNAs (miRNAs) have been reported to play crucial roles in regulating a variety of genes pivotal
for tumor metastasis. MicroRNA-301a (miR-301a) is overexpressed and displays oncogenic activity in many cancers.
However, little is known about the potential roles of miR-301a in colorectal cancer (CRC).
Methods: Taqman probe stem-loop real-time PCR was used to quantitatively measure the expression level of
miR-301a in 48 cases of CRC tissues and the matched adjacent non-tumor mucosa as well as in CRC cell lines.
miR-301a mimics and inhibitors were used to up-regulate and down-regulate miR-301a in CRC cells, respectively;
lentivirus was used to construct miR-301a stably up- and down-regulated CRC cell lines. Metastasis ability was
evaluated by transwell and wound healing assays while invasion was measured by transwell coated with matrix gel
in vitro; in vivo metastasis was performed on nude mice model. The target of miR-301a was predicted by TargetScan
software and validated by qRT-PCR, immunohistochemistry, western blot and luciferase reporter gene assay.
Results: The expression of miR-301a was significantly higher in lymph node metastasis positive CRC samples
compared with negative ones. Downregulation of miR-301a significantly inhibited the migration and invasion both
in vitro and in vivo while forced up-regulation of miR-301a promoted migration and invasion. TGFBR2 was identified
to be the downstream target of miR-301a. Knockdown of TGFBR2 in cells treated by miR-301a inhibitor elevated
the previously abrogated migration and invasion.
Conclusions: Our data indicated that miR-301a correlated with the metastatic and invasive ability in human
colorectal cancers and miR-301a exerted its role as oncogene by targeting TGFBR2.
Keywords: CRC, miRNA-301a, Metastasis, Invasion, TGFBR2Background
Colorectal cancer (CRC) is one of the most prevalent
causes of cancer-related mortalities worldwide, with
610.000 deaths each year. Though efforts have been paid
to the prevention of CRC, the incidence of CRC is still
increasing in the past decades [1]. It has been reported
that approximate 20% of CRC patients are diagnosed
with metastases and 50% of early stage CRC patients
treated will eventually develop metastases [2,3]. Despite
advantages in early screening and development of new
therapeutic strategies, the 5-year survival rate for patients* Correspondence: mingliang-99@hotmail.com
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unless otherwise stated.with metastatic CRC is only about 10% [2]. Thus, an
insight into the molecular mechanisms of CRC metastasis
is important for developing new prognostic and thera-
peutic molecular markers to reduce CRC metastasis.
MicroRNAs (miRNAs) are a class of small non-coding
RNAs (18–22 nt in length) which regulate the expres-
sion of target genes by binding to the 3’ un-translated
regions (3’-UTR) [4,5]. Emerging evidences strongly sug-
gest critical roles of miRNAs in the pathogenesis of cancer,
and specially, the tumor metastasis [6,7]. The dysregula-
tion of miRNAs in CRC has been reported using miRNA
expression profiling studies with different miRNAs iden-
tified either as enhancers (miR-21, miR-31, miR-103,
miR-107) or suppressors (miR-135, miR-145, miR-200c)
in the initiation and evolution of tumor metastasis [8-13].
Considering the chemical stability, the ease of clinicalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pathology, researches on the identification of potential
miRNAs as metastatic biomarkers and therapeutic tar-
gets in CRC patients are rapidly increasing.
The gene encoding miR-301a is located in the human
chromosome 17q22-17q23 and it has been previously re-
ported to be overexpressed in many kinds of human
cancers, including gastric cancer, liver cancer, breast
cancer, etc. [14-20]. Besides, a series of recent functional
studies demonstrated that miR-301a promoted cancer
cell metastasis in breast, hepatocellular and gastric tumors
through different target genes [17,21,22]. For CRCs, a
miRNA array which analyzed the miRNA expression pro-
files of 44 pairs of CRCs revealed that the expression of
miR-301a was elevated in tumor tissues of stage II patients
compared to paired normal tissues [23]. However, until
now, functional evidence of miR-301a in CRCs has not
been documented and its role in CRC metastasis remains
unclear. Thus, we wanted to know whether miR-301a was
involved in the metastasis of CRC and we further wanted
to evaluate the potential signalling pathways through
which miR-301a regulated metastasis.
Methods
CRC samples
48 pairs of tumor samples and the paired adjacent non-
tumor mucosa (at least 5 cm away from the tumor margin)
were collected from CRC patients undergoing laparo-
scopic surgery from March 2011 to September 2011 at
Shanghai Minimally Invasive Surgery Centre (Ruijin Hos-
pital, Shanghai Jiao Tong University School of Medicine).
The written informed consents were given by all patients
prior to surgery and all procedures were approved by the
ethics committee of Ruijin Hospital. None of the patients
received preoperative chemoradiotherapy and all were di-
agnosed with resectable tumors by endoscopy and CT. All
tumors were confirmed pathologically and classified ac-
cording to the 7th edition of AJCC/UICC TNM system
[24]. The clinicopathological information of included cases
was prospectively collected during hospitalization. Sam-
ples were immediately excised and preserved in formalin
for further immunohistochemical staining or snap-frozen
in liquid nitrogen for future RNA extraction.
Cell culture
Five human CRC cell lines were obtained from American
Type Culture Collection (Manassas, United States). HCT116
and HT29 were cultured in Dulbecco’s modified Eagle’sTable 1 Primer sequences used qRT-PCR
Forward primer
TGFBR2 5′-GTAGCTCTGATGAGTGCAATGAC-3
GAPDH 5′-CGGAGTCAACGGATTTGGTCGTAT-medium (DMEM; Gibco, United States) with 10% fetal bo-
vine serum (FBS). LOVO, SW480 and SW620 were main-
tained in RPMI 1640 (Sigma Aldrich, United States),
supplemented with 10% FBS. All cells were maintained in
a humidified incubator at 37°C with 5% CO2.
RNA isolation and miRNAs assays
Total RNA was isolated from cell lines and tissue samples
using Trizol reagent (Invitrogen, United States) according
to the manufacturer’s instructions. The expression levels
of miR-301a and U6 small nuclear RNA (RNU6B, Applied
Biosystems, United States) were assayed in triplicates by
the TaqMan stem-loop RT-PCR method with a mirVana
miRNA detection Kit and gene-specific primers (Applied
Biosystems, United States). Expression levels of RNU6B
were used for normalization. The relative expression of
miR-301a in tissues and cell lines were calculated by the
2-Δct method.
SYBR green real-time RT-PCR
The mRNA level of TGBR2 was measured by quantita-
tive real-time polymerase chain reaction (qRT-PCR) with
Power SYBR Green PCR Master Mix (Applied Biosys-
tems, United States) in an Applied Biosystems 7500 Sys-
tem. The Super Script III First-Strand Synthesis System
(Invitrogen, United States) was used to prepare cDNA
from total RNA. The primers for TGFBR2 gene were ob-
tained from “Primerbank” (http://pga.mgh.harvard.edu/
primerbank/). The relative amount of TGFBR2 mRNA was
uniformly normalized using glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) as endogenous control. Primer
sequences are presented in Table 1.
Oligonucleotides transfection
miR-301a inhibitors (anti-miR-301a), miR-301a mimics
and their corresponding negative controls (anti-miR-
NC, miR-NC) were purchased from GenePharma (China,
Table 2). siRNA of TGFBR2 was purchased from
Dharmacon (D-003930, Dharmacon, United States). Cells
were transfected with 100 nM oligonucleotides using
Lipofectamine 2000 Reagent (Invitrogen, United States)
according to the manufacturer’s instructions. 48 hours
after transfection, cells were harvested and miR-301a
expression level was monitored by qRT-PCR (U6 RNA was
endogenous control), and the siRNA transfection efficiency
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Plasmids LV3-pGLV-H1-GFP + Puro with hsa-miR-301a
inhibitor or its negative control oligonucleotides, namely
LV-anti-miR-301a and LV-anti-miR-301a-NC, were pur-
chased from GenaPharma (China). The procedures to
establish LV-anti-miR-301a stably expressing clones and
the control clones in SW620 cells (SW620/LV-anti-miR-
301a and SW620/LV-anti-miR-NC) were performed as
previously described [25].
Migration and invasion assays
Cell migration was performed using transwell inserts
(Corning, United States), and cell invasion assay was
measured using matrigel-coated upper chambers (BD
Bioscience, United States). Briefly, cells (2.5 × 105) in 200
μl serum-free medium were plated to the upper cham-
bers and medium containing 10% serum was used as
chemo attractant in lower chambers. After 24 hours in-
cubation, non-migrating or non-invading cells were re-
moved softly with cotton swabs and cells at the out
surface of insert membranes were fixed with menthol for
30 min, stained with 1% crystal violet for another 30
min, and then photographed under 200 × magnification.
Cells were counted from 5 random fields of view and
means ± SD were calculated accordingly.
Wound-healing assay
Generally, cells were first plated in a six-well plate and
then transfected with different oligonucleotides. Forty-
eight hours later, cells were harvested and plated in a new
six-well plate. When the cells grew to a confluence of 90–
95%, the cell monolayer was scratched using a sterile 10 μl
pipette tip. After washing and removing the detached
cells, the plates were incubated at 37°C for 24 h and the
wounds were photographed. Then the open wound area
was quantified using “TScratch” as previously described
[26]. At least 5 different wounds were performed, and the
experiments were repeated 3 times independently.
In vivo metastasis assay
SW620/LV-anti-miR-301a and SW620/LV-anti-miR-NC
cells (5 × 106 cells per mice) were implanted subcutane-
ously into the left flanks of 5-week-old male nude mice
(10 mice per group). Local invasion and lung metastasiswere examined 4 or 7 weeks after implantation respectively
(5 mice per group for each). Tumors and lungs were har-
vested, fixed, embedded and stained with haematoxylin
and eosin as described previously [27]. All animal experi-
ments complied with protocols approved by the Animal
Care and Use Committee of Shanghai Jiao Tong Univer-
sity School of Medicine.
Western blot analysis
Whole cell protein lysates were extracted using M-PER re-
agents and Halt Protease Inhibitor Cocktail kits (Pierce,
United States). The protein concentrations were quantified
with a Bicinchoninic Acid (BCA) protein assay kit (Pierce,
United States). Western blotting for TGFBR2 was per-
formed with established procedures as Ye et al. described
previously [28]. The mouse monoclonal anti-TGFBR2
antibody (1:500, Abcam, United States) and anti-GAPDH
antibody (1:2000, Kang Chen, China) were used as the pri-
mary antibodies. GAPDH served as loading control.
Immunohistochemistry analysis
Immunohistochemistry analysis of TGFBR2 was per-
formed with an anti-TGFBR2 antibody (1:200, Abcam,
United States). Tumor tissues were fixed, embedded and
stained with haematoxylin and eosin (Sigma, United
States). Immunohistochemistry staining was performed
with established protocols [29]. Relative TGFBR2 expres-
sion were defined as positive (moderate or strong stain-
ing) and negative (no or weak staining) based on the
intensity of TGFBR2 staining of the tumor cells.
Vector construction and luciferase reporter assay
miR-301a binding sites were predicted using TargetScan
software (http://www.targetscan.org) and target genes
which had the highest possibility and were also metastasis
related were chosen for further validation. Bioinformatics
analysis revealed two putative binding sites for miR-301a:
a conserved 7mer-m8 at nt 266-272 of TGFBR2 3’-UTR
and a poorly conserved 7mer-m8 at position 566-572 of
TGFBR2 3’-UTR. Two mutant fragments of TGFBR2 3’-
UTR (mut-266, mut-566) were designed using a Quick
Change Site-Directed Mutagenesis kit (Stratagene, United
States). Then the full length of miR-301a TGFBR2 3’-UTR
including two wild-type binding sites and the two mutant
fragments (mut-266, mut-566) were designed by and pur-
chased from Sangon (Shanghai, China). After digestion by
Sac I and Hind III, the fragments of wild-type and mutant
were cloned into the Sac I and Hind III sites of pMIR-
Report Luciferase Vector (Applied Biosystems, United
States) and were named pMIR/TGFBR2-wt, pMIR/TGFBR2-
mut-266 and pMIR/TGFBR2-mut-566, respectively. All
constructs were verified by Sanger sequencing.
SW620 cells were co-transfected with 200 ng luciferase
reporter gene construct, 2 ng pRL-TK vector (Promega,
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mimics or inhibitor in 24-well plates. Reporter assays
were performed 48 h post-transfection using the Dual-
luciferase assay system (Promega, United States). Firefly
luciferase activity was normalized to renilla luciferase ac-
tivity. All transfection experiments were conducted in
triplicate and repeated 3 times independently.
Statistical methods
Data were expressed as means ± standard deviation (SD)
and P < 0.05 was considered statistically significant. Stu-
dent’s t test (two-tailed) was used to compare two
groups unless indicated specifically (χ2 test was used for
comparison of the rates of two groups). Correlation ana-
lysis was performed with spearman correlation analysis.
All statistical analyses were performed using the SPSS
15.0 software (SPSS Inc, United States).
Results
miR-301a is up-regulated in lymph node metastatic CRC
tissues and CRC cells lines
To understand the role of miR-301a in CRC progression,
we examined the expression of miR-301a in 48 CRCFigure 1 miR-301a was upregulated in lymph node metastatic CRC ti
pairs of CRC samples and matched adjacent normal mucosa; U6 small nuc
difference in miR-301a expression between CRC tissues and their adjacent
lymph node metastasis were much higher than that of CRCs without lymp
migration assays. (D) Relative expression of miR-301a in 5 CRC cell lines by
representedas means ± SD from 3 independent experiments. #, P > 0.05; *, Ptissues and their paired adjacent non-tumor tissues. qRT-
PCR demonstrated that there was no significant difference
of miR-301a expression between CRC and the adjacent
non-tumor mucosa (Figure 1A, P > 0.05). However, the ex-
pression of miR-301a in tumors with lymph node metasta-
ses was significantly higher than that in tumors without
metastases (Figure 1B, P < 0.05), which indicated that
miR-301a might be involved in the metastasis of CRC.
Importantly, the expression of miR-301a did not differ
among patients with different gender, age, tumor differen-
tiation, tumor location, tumor histopathology, tumor local
invasion or distant metastasis (Table 3).
Next we wanted to know whether miR-301a was ex-
pressed in CRC cell lines with differential metastatic po-
tential and whether the expression was associated with
the metastatic ability. We conducted the migration assay
with five CRC cell lines and found SW620 and HCT116
cells exhibited high metastatic ability while LOVO being
the moderate and HT29 and SW480 as less metastatic
cell lines (Figure 1C). Subsequently, we evaluated the
expression of miR-301a in these cells and as shown in
Figure 1D, the expression of miR-301a was much higher
in SW620 and HCT116 than that of LOVO, HT29, andssues and highly metastatic CRC cells. (A) qRT-PCR analysis of 48
lear RNA was used as an internal control. There was no significant
non-tumor tissues. (B) miR-301a expression levels in primary CRCs with
h node metastasis. (C) The migratory potential was examined by
qRT-PCR with U6 small nuclear RNA as an internal control. Data were
< 0.05; **, P < 0.01.
Table 3 Clinicopathological parameters
Characteristics No. of cases miR-301 expression P-value
Age(years)
<66 20 3.76
≥66 28 3.63 0.79
Sex
Male 30 3.60
Female 18 3.83 0.62
Tumor location
Colon 23 3.27
Rectum 25 4.07 0.08
Tumor invasion
T1, T2 10 3.03
T3, T4 38 3.86 0.14
Lymphatic metastasis
Positive 26 3.16
Negative 22 4.08 0.03
Distant metastasis
M0 43 3.72
M1 5 3.40 0.68
Differentiation
Well and Moderate 34 3.91
Poor 14 3.14 0.13
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be correlated with the metastatic ability of CRC cells by
spearman correlation analysis (r = 0.96, P < 0.01).
Altogether, these data indicated that miR-301a may con-
tribute to the metastasis of CRC.
miR-301a promotes CRC cell migration and invasion
in vitro
To further determine whether miR-301a could affect
CRC cell migration, we transfected SW620 cells, which
showed a high level of miR-301a, with the anti-miR-301a
in order to suppress miR-301a (i.e. SW620/anti-miR-
301a cells). Meanwhile, anti-miR-control was transfected
as negative control (i.e. SW620/anti-miR-NC cells). Tran-
sient transfection of anti-miR-301a in SW620 cells
significantly suppressed the expression of miR-301a in
SW620/anti-miR-301a cells (Figure 2A, P < 0.01). Next we
conducted cell migration assay to evaluate whether miR-
301a could influence metastasis directly. As shown in
Figure 2C, SW620/anti-miR-301a cells showed a signifi-
cant (P < 0.01) reduction of migratory ability, while, unex-
pectedly, the invasive capacity was also significantly (P <
0.01) decreased. To further support the role of miR-301a
in migration, we performed the wound-healing assays
to explore cell motility change. In consistent with themigratory change, SW620/anti-miR301a cells exhibited
significant lower migratory potential compared with the
control cells (Figure 2E, P < 0.01).
Additionally, the gain-of-function assay with miR-301a
mimics transfected in miR-301a low-expressed SW480
cells was performed to further consolidate the role of
miR-301a in cell migration and invasion. As shown in
Figure 2B, exogenous expression of miR-301a in SW480
cells resulted in a significant increase of miR-301a by
qRT-PCR (P < 0.01). Upregulation of miR-301a in SW480
cells led to a marked increase of both migratory and inva-
sive abilities in contrast with the control cells (Figure 2D,
P < 0.01). Consistently, SW480 cells transfected with miR-
301a mimics migrated much faster than the control cells
in the wound-healing assay (Figure 2F, P < 0.01). Conclu-
sively, miR-301a promotes the migration and invasion
ability of CRC cells in vitro.
miR-301a promotes tumor metastasis and cell invasion
in vivo
The above mentioned results further led us to ask whether
miR-301a functioned as a promoter of migration and inva-
sion of CRC cells in vivo as well. To this end, we con-
structed miR-301a stably down-regulated and negative
control SW620 cells with lentivirus particles LV-anti-miR-
301a and LV-anti-miR-301a-NC, respectively. SW620/LV-
anti-miR-301a cells and SW620/LV-anti-miR-NC cells
were separately injected into nude mice subcutaneously
and mice were sacrificed four weeks later. Tumors were
processed and stained with H&E staining. As shown in
Figure 3A, tumors grown of SW620/LV-anti-miR-301a
cells were less-invasive as most tumors (4/5) confined
within the fibrous capsules without breaking into the stro-
mal (Figure 3A, right panel). In contrast, tumors of the
control group had cancer nests formed by SW620/LV-
anti-miR-NC cells which invaded the adjacent stromal tis-
sues (Figure 3A, left panel).
To validate the role of miR-301a in metastasis in vivo,
we dissected the lung of nude mice and evaluated the
metastatic sites both micro- and macroscopically. In line
with the in vitro results, fewer metastatic lesions in the
lung of nude mice injected with SW620/LV-anti-miR-301a
were seen compared with that of SW620/LV-anti-miR-NC
group (Figure 3B; P < 0.05), indicating the suppression of
metastatic ability in SW620/LV-anti-miR-301a cells in vivo.
Hence, miR-301a could promote tumor metastasis and
invasion in vivo.
miR-301a represses TGFBR2 protein expression by
binding to 3’-UTR
It’s well-established that miRNAs exert their biological
functions by binding to the 3’-UTR and inhibiting the
translation of their target genes. Thus we wanted to know
the target through which miR-301a exerted its function in
Figure 2 (See legend on next page.)
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Figure 2 miR-301a promoted CRC cell migration and invasion in vitro. (A) Expression levels of miR-301a in SW620 cells after transfection
with inhibitors of miR-301a, as determined by qRT-PCR. U6 small nuclear RNA was used as an internal control. (B) Expression levels of miR-301a in
SW480 cells after transfection with synthetic miR-301a mimics, as determined by qRT-PCR. U6 small nuclear RNA was used as an internal control.
(C) Downregulation of miR-301a with its inhibitors impeded cell migration and invasion of SW620 cells. (D) Overexpression of miR-301a significantly
promoted cell migration and invasion in SW480 cells. (E) miR-301a inhibitors significantly inhibited SW620 cell motility as shown in wound healing
assay. (F) miR-301a mimics significantly promoted SW480 cell migration in wound healing assay. Data were representedas means ± SD from 3
independent experiments. **, P < 0.01.
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to predict the potential targets of miR-301a. By searching
the online TargetScan and PicTar algorithms systems, we
identified transforming growth factor receptor 2 (TGFBR2)
as the target of miR-301a with the highest possibility.
TGFBR2 is a major trans-membrane receptor of trans-
forming growth factor-β (TGF-β). Upon binding with its
ligand TGF-β, TGFBR2 is phosphorylated at the serine
and threonine residues within its GS box, which could ac-
tivate the TGF-β signaling pathway and lead to acquisition
of resistance to the anti-mitogenic effects of TGF-β and
contribute to tumor development and progression [30,31].
Thus, we attempted to figure out whether TGFBR2
was a downstream target of miR-301a or not. qRT-PCR
and western blot analysis were first employed and some-
how unexpectedly, there was no significant difference of
TGFBR2 mRNA levels between SW620/anti-miR-301a
and SW620/anti-miR-NC cells or SW480/miR-301a and
SW480/miR-NC cells (Figure 4A). However, western
blot demonstrated that expression of TGFBR2 protein
was markedly increased in miR-301a downregulated
SW620 cells and significantly reduced in miR-301a over-
expressed SW480 cells (Figure 4B). This suggested that
miR-301a suppressed TGFBR2 by post-transcriptional
mechanism rather than directly inhibiting the transcrip-
tion. Besides, suppression of TGBFR2 by miR-301a was
also validated in vivo: in the xenograft tumors from
SW620/LV-anti-miR-301a nude mice, staining intensity
of TGFBR2 elevated remarkably compared to that of the
SW620/LV-anti-miR-NC tumors (Figure 4C). Combined
together, these results suggested that miR-301a sup-
pressed TGFBR2 in CRC cells.
We then wanted to know the mechanism through
which miR-301a regulated TGFBR2. In the 3’-UTR of
TGRBR2 mRNA there existed two putative binding sites
for miR-301a: a highly conserved 7mer-m8 at nt 266-
272 and a poorly conserved 7mer-m8 at position 566-
572 (Figure 4D). To clarify whether miR-301a could
interact with the 3’-UTR of TGFBR2, we performed lu-
ciferase reporter assays. Wild type and two mutant frag-
ments of 3’-UTR were co-transfected with miR-301a
mimics or NC, respectively. As shown in Figure 4E,
compared to the miR-NC, miR-301a mimics significantly
(P < 0.01) reduced the relative luciferase activity of pMIR/
TGFBR2-wt and pMIR/TGFBR2-mut566 of TGFBR2.However, miR-301a did not affect the relative lucifer-
ase activity of the pMIR/TGFBR2-mut266, suggesting
that miR-301a specifically bind to the conserved 7mer-m8
at nt 266-272 on 3’-UTR of TGFBR2. These data de-
monstrated unambiguously that miR-301a suppressed
TGFBR2 protein expression via targeting its specific
RNA binding site.
TGFBR2 is a functional target through which miR-301a
regulated metastasis and invasion in CRC cells
The results presented above confirmed TGFBR2 as one
downstream target of miR-301a; however, it remained
unclear whether miR-301a regulated metastasis and in-
vasion in CRC cells through modulating TGFBR2. To
this end, we focused on whether artificial expression or
suppression of TGFBR2 protein could offset the effects
caused by miR-301a mimics or anti-miR-301a, respect-
ively. First, siRNA targeting TGFBR2 was transiently
transfected into SW480 cells and as shown in Figure 5A,
expression of TGFBR2 was markedly suppressed and this
resulted in enhanced migration and invasion in SW480
cells (Figure 5B, P < 0.01), suggesting the involvement of
TGFBR2 in CRC cell metastasis and invasion.
To further determine whether TGFBR2 is responsible
for the migration and invasion caused by miR-301a, we
transfected TGFBR2 siRNA into SW620/LV-anti-miR-
301a cells transiently. As shown in Figure 5C, the en-
hanced TGFBR2 level by LV-anti-miR-301a was depleted
upon TGFBR2 siRNA transfection. Remarkably, com-
pared with the SW620/LV-anti-miR-301a cells treated
with siRNA/NC, SW620/LV-anti-miR-301a cells trans-
fected with TGFBR2 siRNA regained the previously abro-
gated migration and invasion ability (Figure 5D, P < 0.01).
Additionally, we evaluated the expression of TGFBR2 in
CRCs. The archived tumors of the included 48 cases were
retrieved and stained. As shown in Figure 6, higher
TGFBR2 staining positivity was seen in tumors with low
miR-301a expression; furthermore, we quantified the
TGFBR2 staining intensity and made a correlation analysis
between TGFBR2 and miR-301a. Expression of TGFBR2
was significantly and inversely associated with the expres-
sion of miR-301a (r = -0.72, P < 0.001). Conclusively, these
results suggest that downregulation of TGFBR2 is involved
in miR-301a-induced metastasis and invasion; TGFBR2 is
a functional target of miR-301a.
Figure 3 Downregualtion of miR-301a suppressed CRC cell invasion and lung metastases in vivo. (A) miR-301a inhibited CRC cell invasion.
H&E staining of tumor acquied from nude mice bearing the SW620/LV-anti-miR-301a or SW620/LV-anti-miR-NC cells (indicated by arrows), 4
weeks post implantation. (B) Mean lung metastatic nodules (left) and histologic analysis (H&E staining) of lung (right) 7 weeks post implantation.
Metastatic tumor lesions are indicated by arrows. Data were represented as means ± SD. Magnification, ×200. Scale bars, 100 μm. *, P < 0.05.
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Cancer metastasis is a complex, multi-step process
which includes intricate cascades of molecular events.
It’s well-established that miRNAs are involved in CRC
tumorigenesis and many of them can serve as activators
or suppressors of CRC metastasis [8-10,13]. miR-301a,
one micro-RNA reported to be expressed at different
levels in a variety of cancers, has been demonstrated to
be important in promoting cancer metastasis [17,21,22].However, the expression of miR-301a in CRCs and its
role in CRC metastasis remain unclear. In the current
study, we reported for the first time that miR-301a
was up-regulated in lymph node metastatic CRC tis-
sues and promoted CRC metastasis both in vitro and
in vivo. Furthermore, we identified TGFBR2 to be
one downstream target of miR-301a and also the ef-
fector of miR-301a in the regulation of metastasis in
CRC cells.
Figure 4 TGFBR2 was a direct target gene of miR-301a. (A) qRT-PCR showed that neither miR-301a mimics nor anti-miR-301a changed the
mRNA level of TGFBR2. (B) anti-miR-301a in SW620 cells suppressed, while miR-301a mimics in SW480 cells increased the protein expression of
TGFBR2. (C) Immunohistochemical staining of TGFBR2 in tumor sections. Expression of TGFBR2 was evaluated in tumors formed by SW620/LV-
anti-miR-301a cells. (D) Schematic picture of two miR-301a binding sites and the corresponding mutants on TGFBR2 3’-UTR. (E) Luciferase activity
assay identified the binding sites of miR-301a. Data were representedas means ± SD from 3 independent experiments. Magnification, ×200. Scale
bars, 100 μm. *, P < 0.05; **, P < 0.01.
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types of human cancers and proved to be an oncogene
in gastric cancer [22], pancreatic cancer [32], hepatocel-
lular cancer [21], and esophageal cancer [33]. In this
study, we investigated the expression of miR-301a in
CRC specimens for the first time. Unlike its expressions
in the cancers mentioned above, there is no statistical
difference of miR-301a expression between CRC tissuesand their adjacent non-tumor tissues, nevertheless, in-
creased miR-301a expression was observed in tumors with
lymph node metastasis. This was in consistent with its
role as an oncogene in aforementioned cancers and might
indicate a metastasis promotion role rather than a tumor
initiation role of miR-301a in CRCs. In supporting this, we
found CRC cell lines with high metastasis capacity
expressed higher miR-301a than those with low metastasis
Figure 5 miR-301a regulated metastasis and invasion through suppressing TGFBR2 in CRC cells. (A) Western bloting showed TGFBR2 was
downregulated in SW480 cells transiently transfected with TGFBR2 siRNA. (B) The cell invasion and migration ability were improved in TGFBR2
downregulated SW480 cells. (C) Expression of TGFBR2 protein in SW620/LV-anti-miR-301a or SW620/LV-anti-miR-NC cells transiently transfected
with TGFBR2 siRNA or siRNA/NC. (D) Cell invasion and migration assays of SW620/LV-anti-miR-301a or SW620/LV-anti-miR-NC cells transiently
transfected with TGFBR2 siRNA or siRNA/NC. Data were representedas means ± SD from 3 independent experiments. **, P < 0.01.
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miR-301a expression was correlated positively with the
cell migratory ability in these CRC cells. These data led
us to ask whether miR-301a could regulate metastasis in
CRCs or not.Figure 6 Immunohistochemical staining of TGFBR2 in CRCs. Higher ex
level (r = -0.72, P < 0.001). Magnification, ×200. Scale bars, 100 μm.Actually, previous studies have shown that miR-301a
acted as a metastatic promoter in different kinds of hu-
man cancers. Shi et al first reported the expression of
miR-301a in human cancer: miR-301a overexpression
has been implicated as a negative prognostic indicator inpression of TGFBR2 was observed mainly in CRCs with low miR-301a
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strongly associated with tumor recurrence. Besides knock-
down of miR-301a reduced migration and invasion of both
MCF-7 and MDA-MB-231 breast cancer cell lines in vitro
[17]. Likewise, a recent study described that the expression
level of miR-301a was significantly elevated in the primary
tumors of 10 breast cancer patients with distant metasta-
sis, as compared with that in primary tumors from 10
patients without detectable distant metastasis [34]. Add-
itionally, overexpression of miR-301a in breast cancer cell
lines could promote cell migration and invasion in vitro
and lung metastases in mice models. Moreover, downreg-
ulation of miR-301a in hepatocellular carcinoma (HCC)
cells suppressed invasion and migration of HCC cells
in vitro [21]. In gastric cancer cells, ectopic expression of
miR-301a led to significantly enhanced cell migration and
invasion, whereas knockdown of miR-301a also inhibited
cell metastasis [22].
In line with these findings, we demonstrated that over-
expression of miR-301a in less aggressive SW480 cells
led to a significant increase of cell migration whereas
downregulation of miR-301a in more aggressive SW620
cells resulted in decreased migratic ability, indicating
the metastasis promoter role of miR-301a in CRC.
Furthermore, this effect was also prominent in vivo:
knockdown of miR-301a significantly reduced xenograft
tumor invasion and lung metastases in nude mice. These
results indicated that miR-301a is a metastatic promoter
in CRC.
miRNAs exert their biological functions by binding
with the 3’-UTR of their target genes. Thus, identifying
the downstream target genes could help understand
miRNA physiological and pathological roles. Though sev-
eral approaches have been developed to search miRNA
targets in recent years, the computational approach, a
method based on the principle that all known miRNA tar-
gets have conserved perfect or near-perfect complemen-
tary sites for miRNAs, was a powerful and prevalently
used strategy [35-37]. Thus, we used the online TargetScan
and PicTar algorithms systems to search for potential tar-
gets of miR-301a. As a result, TGFBR2, a gene previously
reported involved in metastasis, was identified to be the
target with highest possibility.
TGFBR2, a trans-membrane serine-threonine kinase,
is a major member of TGF-β signaling and often found
to be altered in CRCs [38]. The TGF-β signaling pathway
plays a complex role in several CRC biological processes,
including cell differentiation, proliferation, apoptosis, and
motility [39]. It is commonly speculated that CRCs acquire
partial TGF-β resistance largely because of TGFBR2
inactivation. Importantly, TGFBR2 is a metastatic suppres-
sor in CRC: previous research showed that downregula-
tion of TGFBR2 increased migration and invasion of
HT29 cells in vitro [27] whereas evidences from in vivostudies suggested that loss of TGFBR2 contributed to
colon cancer development and metastasis in cooperation
with mutant K-ras or in the context of PTEN loss [40,41].
Indeed we found TGFBR2 was one target of miR-301a
and the luciferase reporter gene assay successfully identi-
fied the binding site for miR-301a on the 3’-UTR of
TGFBR2 gene. In consistent with this, we found knock-
down of miR-301a in CRC cells upregulated the protein
level of TGFBR2 while ectopically overexpression of miR-
301a suppressed its expression. Supporting this, we ob-
served an inverse correlation between miR-301a and
TGFBR2 protein expression in CRC tumor tissues. Func-
tionally, we found TGFBR2 acted as a metastasis sup-
pressor and also the effector of miR-301a in CRC cells:
knockdown of TGFBR2 induced a significant increase in
motility and invasiveness of SW480 cells whereas downreg-
ulation of TGFBR2 also elevated the previously abrogated
migration and invasion ability initiated by LV-anti-miR-
301a in SW620 cells. Taken together, TGFBR2 played an
important role in miR-301a mediated tumor migration
and invasion in CRC.
Interestingly, we found miR-301a regulated TGFBR2
expression by some translational suppression mecha-
nisms: the mRNA level of TGFBR2 did not change sig-
nificantly upon transfection with miR-301a inhibitor or
mimics while the protein level showed remarkable differ-
ences. It’s proposed that miRNAs exert their functions
in two ways: when an miRNA perfectly or near-perfectly
pairs with its target mRNAs, it was thought that mRNA
cleavage is the primary mechanism for miRNA mediated
gene regulation; in case of a miRNA imperfectly pairs
with its target mRNAs, translational suppression is
thought to happen with protein expression downregu-
lated while mRNA level remained stable [42,43]. In this
study, though we found miR-301a indeed bound with
TGFBR2, they might not perfectly match in sequence
since we observed marked downregulation of TGFBR2
protein while the mRNA of TGFBR2 remained unchanged.
Thus we suggest that miR-301a imperfectly bind with the
3’-UTR of TGFBR2 and regulate the expression of TGFBR2
via translational suppression.
Conclusions
In summary, our study presented convincing evidences
to show that miR-301a exerted its role as oncogene in
CRC metastasis, and for the first time we identified
TGFBR2 as a functional target involved in miR-301a
modulated CRC cell metastasis. miR-301a could be
regarded as a new target for CRC prevention and therapy.
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